Women with alopecia areata (AA), especially those with severe symptoms and lower income, face significant financial burden managing the condition.
Patients with alopecia areata (AA), particularly women, as well as those with severe symptoms and lower-income individuals, experience significant financial strain managing AA treatments and hair regrowth products.
A United Kingdom (UK) online survey completed by 829 participants collected data from May to August 2022 using Qualtrics. Disease duration, hair loss, and quality of life (QoL) were assessed using validated scales. Usage of products and services to manage AA was observed over the preceding 12 months as well as from the time of diagnosis up until the preceding 12 months.
The AA Symptom Impact Scale—Severity Subscale rated the severity of 7 symptoms from 0 (not present) to 10 (as bad as you can imagine) over the preceding week. The AA Patient Priority Outcomes—Hair Loss items measured the current severity of hair loss on the scalp, eyebrows, eyelashes, and body using a 5-point scale from 0 (no hair loss) to 4 (complete hair loss). Overall quality of life (QoL) impacted from products and services were measured from 1 (made things much worse) to 5 (made things much better).
The participants were mostly female (85.9%) and White (92.7%), had an average age of 42.7 years old, and had a median AA diagnosis duration of 10.9 years. Notably, men used fewer products to manage AA compared with women before and during the preceding year, except for hats (49.5% vs 45.4%), vitamins/supplements (38% vs 38.3%), non-prescription shampoos (36.2% vs 37.3%), and other non-prescription scalp treatments (21% vs 20.6%).
Patients with AA over the past year chose, "made things a little better" as the most common response (35.5%), followed by "made no difference" (34.2%) and "made things much better" (20.4%) based on the impact the products and services had. A small portion (10.0%) reported negative impacts.
A median total cost of $1,012.60 over the preceding 12 months was reportedly spent by individuals with AA on products and services to manage the disease. Women had significantly higher average total costs than men ($1,174.94 vs $195.82).
Wigs were the most common expense for women ($884.36), followed by eyebrow and eyelash products ($252.68). For men, private dermatology services were the most expensive ($694.86), though only 14 of 107 participants used them. The median percentage of participants' absolute cost as it relates to income was 3.6% for women and 0.3% for men. The most common strategy to manage expenses was using own savings (about 40%), while the least common was borrowing money from the bank (about 4%).
Annual average spending on AA products and services is 3%, equal to one-third of the UK's average household energy cost. While hair loss location didn’t impact financial burden, overall symptom severity did. Lower income individuals experienced a greater financial burden, suggesting similar spending across income levels, implying participants view these products and services as essential regardless of income.
Spending on AA products and services increased based on symptom severity, lower income, and Asian ethnicity. Limited product availability for Asians necessitated seeking specialist options, leading to higher costs.
The impact on QoL conferred by products and services varied based on individual perception. While some women found wigs reduced negative evaluation fear, they also worried about being discovered. Conversely, men preferred medical solutions over cosmetic products.
Study limitations included the lack of representation and generalizability of the survey sample size. Asian ethnicities, Black individuals, men, and people with minimal health service contacts were significantly underrepresented. Predictors of financial burdens could be skewed after failing to report precise salaries which may have introduced measurement error in individual income values.
The authors concluded, “Risk factors require consideration by health providers, commissioners, and policy makers when designing services to support the wellbeing of people living with AA.”
Reference
Zucchelli F, Harries M, Messenger A, Montgomery K. Establishing the financial burden of alopecia areata and its predictors. Skin Health Dis. 2023;4(1):e301. doi:10.1002/ski2.301
Scalp Repair Serum Microneedling: Fewer Treatments, More Hair Regrowth for AGA
May 14th 2024A study found scalp repair serum microneedle combined therapy with medication to improve hair growth outcomes for patients with moderate to severe androgenetic alopecia (AGA) and reduce the number of microneedling sessions necessary.
Read More
Alopecia Areata Risk Associated With Atopy, Allergies
May 13th 2024A genetic study suggests people with allergies and eczema are more likely to develop alopecia areata, an autoimmune disease that causes hair loss. Researchers believe this link may be due to similar immune system responses.
Read More
Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women
May 13th 2024A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Read More
Breast Cancer Treatment Disparities Impact Survival Based on Race, Age, Socioeconomics
May 9th 2024A new study has linked racial and ethnic disparities with factors like age, income, and insurance to breast cancer treatment decline. Patients who received all treatments had better survival, highlighting the need for interventions to improve access and reduce disparities.
Read More
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More